Clinical Trial Update: Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

This update notes the completion of a Phase 1 study evaluating recombinant interleukin-21 in combination with Rituxan for non-Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Recombinant Interleukin-21 (interleukin-21)
• Rituxan (rituximab)

Snippet

Sponsor: ZymoGenetics | Conditions: Lymphoma, Non-Hodgkin | Phase 1 | Status: COMPLETED